SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001104659-23-065542
Filing Date
2023-05-26
Accepted
2023-05-26 17:00:56
Documents
15
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K/A tm2317013d1_10ka.htm   iXBRL 10-K/A 341682
2 EXHIBIT 31.1 tm2317013d1_ex31-1.htm EX-31.1 10269
3 EXHIBIT 31.2 tm2317013d1_ex31-2.htm EX-31.2 10349
  Complete submission text file 0001104659-23-065542.txt   676372

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20221231.xsd EX-101.SCH 3274
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20221231_def.xml EX-101.DEF 28282
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20221231_lab.xml EX-101.LAB 38776
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20221231_pre.xml EX-101.PRE 26892
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2317013d1_10ka_htm.xml XML 8657
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38302 | Film No.: 23970047
SIC: 2834 Pharmaceutical Preparations